Podcasts about Roche

This week we are so excited to bring you our conversation with Laurent Hopman and Renaud Roche, the creators of the upcoming incredible new graphic novel LUCAS WARS. If you don't know about it already, this book tells the epic story of the making of the original STAR WARS in a way never done before and we can't get enough of it. Hear all about how this book came to be, what's to come next and some big folks who've also loved the book. So get on your bike to pick up that TPM bootleg, listen today and celebrate the love! JOIN THE BLAST POINTS ARMY and SUPPORT BLAST POINTS ON PATREON! NEW ANDOR SEASON 2 EPISODE COMMENTARIES! COMMENTARIES FOR EVERY SKELETON CREW EPISODE! NEW EMPIRE STRIKES BACK COMMENTARY! Theme Music! downloadable tunes from episodes! Extra goodies! and so much MORE! www.patreon.com/blastpoints Blast Points T-SHIRTS are now available! Represent your favorite podcast everywhere you go! Get logo shirts while supplies last! Perfect for conventions, dates, formal events and more! Get them here: www.etsy.com/shop/Gibnerd?section_id=21195481 If you dug the show, please leave BLAST POINTS a review on iTunes, Spotify and share the show with friends! If you leave an iTunes review, we will read it on a future episode! Honestly! Talk to Blast Points on twitter at @blast_points "Like" Blast Points on Facebook Join the Blast Points Super Star Wars Chill Group here www.facebook.com/groups/ BlastPointsGroup/ we are also on Instagram! Wow! www.instagram.com/blastpoints Your hosts are Jason Gibner & Gabe Bott! contact BLAST POINTS at : contact@blastpointspodcast.com May the Force be with you, always! This podcast is not affiliated in any way with Lucasfilm Ltd. LLC, The Walt Disney Company, or any of their affiliates or subsidiaries.

(00:00) We start talking about Kowloon, but we quickly shift gears to Joe Murray’s knowledge of food! (18:54) Are the Boston Red legit or are they pretenders? Joe and Roche debate! (32:48) Looks like Bill Belichick is selling some of his real estate on Nantucket. (PLEASE be aware timecodes may shift up to a few minutes due to inserted ads) CONNECT WITH TOUCHER & HARDY: linktr.ee/ToucherandHardy For the latest updates, visit the show page on 985thesportshub.com. Follow 98.5 The Sports Hub on Twitter, Facebook and Instagram. Watch the show every morning on YouTube, and subscribe to stay up-to-date with all the best moments from Boston’s home for sports!

US-Präsident Trump will tiefere Medikamentenpreise und droht mit Zöllen. Nutzen Roche, Novartis und Co. den US-Markt aus? Und, warum fällt es der Branche so schwer Preise zu senken, angesichts der hohen Gewinne und Gehälter? Kritische Fragen an Interpharma-Geschäftsführer René Buholzer. Ergänzend zum Tagesgespräch finden Sie jeden Samstag in unserem Kanal die aktuelle Samstagsrundschau. Die Schweizer Pharma-Industrie steht gleich unter mehrfachem Druck aus den USA: einerseits soll sie die Preise senken für Medikamente in den USA und vermehrt im Land produzieren. Die Industrie hat Milliardeninvestitionen angekündigt, doch dem US-Präsidenten reicht das nicht. Bis Ende September soll die Industrie darlegen, wie sie die Medikamentenpreise, die teilweise ein Mehrfaches über denjenigen in Europa inklusive der Schweiz liegen, senken will. Gelingt das nicht drohen der Branche hohe Zölle. Die Hälfte aller Schweizer Pharma-Exporte gehen in die USA. Wie konnte die Branche so abhängig werden von einem Markt? Warum soll es trotz der hohen Margen im Geschäft nicht möglich sein, die Preise in den USA zu senken, ohne sie in Europa anzuheben? Was hat die Schweiz von Roche, Novartis und Co. tatsächlich? Und, nutzt die Branche die aktuelle Situation, um alte Forderungen nach weniger Regulierung durchzubringen? René Buholzer, der Chef von Interpharma, dem Verband der forschenden Pharmafirmen in der Schweiz, nimmt Stellung in der Samstagsrundschau bei Klaus Ammann.

BlackRock CEO Larry Fink has been appointed interim co-chair of the World Economic Forum, alongside Roche's André Hoffmann, as the organization recalibrates its governance model. It appears the old WEF needs a makeover, as many of the proposals they have been making are now facing defiance. State socialists and stockholder capitalists are now being undermined because of the bullishness from the Trump administration and others who are no longer convinced that their form of world government is key to sustainability models. The goal of the World Economic Forum is to weaponize the future and legitimize a New World Order. We are in a global ideological war between freedom and slavery. Listen to Ground Zero with Clyde Lewis M-F from 7-10 pm, pacific time on groundzeroplus.com. Call in to the LIVE show at 503-225-0860.

Networking for Introverts Who'd Rather Get a Root Canal I Greg Roche Networking advice was built for extroverts. Go to events. Make small talk. Collect business cards. For introverts, it feels like punishment. Exhausting. Fake. Pointless. Greg Roche—known as The Introverted Networker—disagrees. He's living proof you can grow a powerful network without awkward icebreakers, or pretending to be someone you're not. In this conversation, we expose the myths keeping executives stuck—and the truths that set introverts free: Why “I don't have time to network” is a myth How 15 minutes a day beats every networking event How to be “easy to help” so people actually follow through The mic drop: The more connected we get through technology, the less connected we are as humans—because we've outsourced our humanness to tech Plus, a simple, immediate action to restart your network today This isn't about becoming someone you're not. It's about using what makes you different to your advantage—and reclaiming the kind of human connection technology will never replace. Whether you're an introvert who dreads networking—or an extrovert who's been doing it wrong—you'll walk away with a playbook that actually works. Connect with Greg Roche: https://www.linkedin.com/in/gregsroche/ Get his book “The Fast and Easy Guide To Networking For Introverts” here If this episode hit home, do us a solid: leave a review on Apple Podcasts. It helps the show grow, and it helps more executives discover how to thrive in the hidden job market.

Billions are being poured into healthcare AI, yet most innovations never make it past pilot projects. Why? And more importantly—how do we fix it? In this episode of Med Tech Gurus, we sit down with Marco Smit, serial entrepreneur, life sciences executive, and AI commercialization expert. With leadership experience at Roche, Genentech, Gesund.ai, CareSyntax, and now Domelabs.ai, Marco has seen the full spectrum of healthcare AI—from hype to hard-earned success. He shares why so many organizations fall victim to “pilotitis”, the critical role of AI governance, and how startups and health systems can build scalable, evidence-driven solutions that actually deliver ROI. From navigating the complex regulatory landscape to choosing the right investors and partners, Marco offers a pragmatic playbook for moving AI from the lab to real clinical impact. Whether you're a startup founder, health system innovator, or medtech investor, this episode is packed with actionable insights on avoiding hype, accelerating adoption, and building AI solutions that last.

What happens when bureaucracy — the very operating system of most companies — becomes the biggest barrier to innovation, agility, and human potential?In this episode of The Conscious Capitalists' Summer Series, hosts Timothy Henry and Kate Adams speak with Michele Zanini, co-author of the Wall Street Journal bestseller Humanocracy and global expert on management innovation. Together, they explore how organizations can move beyond outdated, control-heavy structures to thrive in a future defined by radical uncertainty, technological disruption, and human ingenuity.Michele takes us inside bold organizational experiments — from Haier's micro-enterprise model in China to Buurtzorg's nurse-led healthcare revolution in the Netherlands — and explains how even giants like Roche are dismantling bureaucracy to become more agile and resilient. His message: organizations that unleash human creativity and distribute leadership will outpace those clinging to industrial-age hierarchy.This isn't just a conversation about management theory — it's a roadmap for building human-centered, future-ready companies that thrive in disruption and unlock the full potential of their people.Listeners will gain insights into:Why traditional bureaucratic models are collapsing — and what's replacing themHow Haier built an internal marketplace of micro-enterprises to fuel innovationBuurtzorg's “humanity over bureaucracy” approach to healthcare at scaleHow Roche transformed by shifting from command-and-control to empowermentThe principle of freedom within a framework — and how to apply itWhy unleashing human creativity is the ultimate competitive advantagePractical steps for leaders to future-proof their organizationsWhether you're a CEO fighting inertia, a startup founder designing for scale, or a leader ready to reimagine culture and structure, this episode offers powerful insights into how to build organizations that are truly capable of thriving into the future.**If you enjoy this podcast, would you consider leaving a review on Apple Podcasts/iTunes? It takes only a few seconds and greatly helps us get our podcast out to a wider audience.Please subscribe on Apple Podcasts / Spotify / Stitcher, or wherever you get your podcasts.For transcripts and show notes, please go to: https://www.theconsciouscapitalists.comThis show is presented by Conscious Capitalism, Inc. (https://www.consciouscapitalism.org/) and is produced by Rainbow Creative (https://www.rainbowcreative.co/) with Matthew Jones as Executive Producer, Rithu Jagannath as Lead Producer, and Nathan Wheatley as Editor.Thank you for your support!- Timothy & Kate

Join Bill Nowicki as he delves into the compelling life of Patrick Roche—a submariner shaped by family tradition, personal responsibility, and decades of experience beneath the waves. From growing up in a Navy family to serving on both diesel boats and missile submarines, Patrick shares intimate reflections on family, service, resilience, and camaraderie in the US Navy's Silent Service.   ### Highlights & Key Points **[00:00:00] - Beginnings in Groton & Naval Heritage** - Patrick grew up in Groton, Connecticut, with his father serving on submarines.   - Graduated high school in 1965; influenced by his father's Navy career.   - Joined the Navy after moving to San Diego (“I guess that's where I got the…”)   - Family tradition: Patrick and his father served together on the USS Ronquil (SS-396), completing three WestPac deployments to Japan and Vietnam.   **[00:03:00] - Life Aboard with Family** - Served with his father but led separate lives aboard; father was a chief quartermaster.   - Never faced negative bias due to his father's position.   Liberty meant different things for each—dad to the chief's club, Patrick and friends to the beach.   **[00:05:00] - Family Life & Responsibility** - Married at age 18, became a father early.   - Now the proud father of four daughters, eight grandchildren, and thirteen great-grandchildren.   - Emphasizes responsibility and “growing up quickly” as a driving force behind his life choices. **[00:09:00] - Naval Career & Historic Moments** - Started as a fireman apprentice with a guaranteed school for submariners.   - Went from diesel to nuclear ballistic missile submarines (SSBNs), including the USS Theodore Roosevelt (SSBN-600).   **[00:12:00] - Life and Duties on Submarines** - Served as an interior communications electrician (“IC man”), specializing as a gyro technician (explains the importance of gyros for navigation and missile launches).   - Patrolled with the George Bancroft (SSBN-643); recalls the predictability of SSBN rotations—three months on, three months off.   **[00:13:00] - Homecomings & Family Dynamics** - Kept family routines stable by letting his wife handle finances and household matters. - No issues adjusting to or from life at sea; credits strong partnership with his wife.   **[00:15:00] - Submarine Evolutions & Technological Changes** - Comments on advancements from older boats to modern fast attacks and Virginia-class submarines. - Describes watchstanding: battle helmsman responsibilities, auxiliary duties, and the unique experience of bunking arrangements.   **[00:19:00] - Challenges & Close Calls** - Survived a major flooding incident on the Roosevelt due to a head valve left open during snorkeling—highlights the ever-present dangers of submarine duty (“…we were down at 80-90 feet with the head valve open…”).   **[00:20:00] - Advancement, Brotherhood & Initiations** - Rose through the ranks to Chief in 12 years; shares stories of chief initiation rites. - Reminisces about camaraderie, qualification processes, and the support systems in place—especially as a “legacy” submariner.   **[00:24:00] - Civilian Career & Life After Service** - Transitioned to civilian roles with NAVSEA (Supervisor Shipbuilding), working in San Diego, New Orleans, and Bath, Maine. - Reflects on moving frequently for assignments, supervising ship construction.   **[00:25:00] - Retirement & Reflections** - Currently resides in Gales Ferry, Connecticut, after retiring 10 years ago. - Considers returning to Maine for its beauty and tranquility. - Stresses the importance of staying in touch with Navy friends and the legacy of the submarine community.   **[00:27:00] - The Holland Club & Submarine Brotherhood** - Member of the US Submarine Veterans' Holland Club—honoring 50+ years of qualification. - Describes the meaning of these traditions and the enduring bonds among submariners.   **[00:29:00] - Lasting Partnerships** - Acknowledges the unwavering support of his wife, Barbara, throughout their 60 years of marriage. - Offers closing reflections on the rewards of naval service and maintaining life-long friendships.   ---   ### Notable Quotes: - “I had a responsibility and had to do it.” - “People treated you a lot different, too, when you're not dink (delinquent in qualifications).” - “I just enjoyed being on the boats—wouldn't trade it for anything.” - “She [his wife] is a winner. Sixty years coming up in December.”   ---   ### Listen For: - Insights into multi-generational Navy life (00:00:00–00:04:00) - Early marriage and parenting in the military (00:05:00–00:07:00) - Historic submarine incidents (00:09:00–00:10:00) - Submarine technology and daily operations (00:12:00–00:16:00) - The legendary Holland Club tradition (00:27:00)   ---   ### Closing   **Want to hear more voices from beneath the waves? Subscribe and leave us a review!**   **Got a story to share, or questions for a guest? Email us or visit our site to connect.**   ---   **Contact & Resources:**   - Want to learn about the Holland Club? [USSVI Holland Club](https://www.ussvi.org/) - More about the Nautilus Memorial: [Submarine Force Museum](https://www.ussnautilus.org/)

Full interview: After a delay, the Government named Ministry for Primary Industries' John Roche as the Prime Minister's new chief science advisor. With the Government prioritising economic growth in its efforts in science, Roche reflects on the pressures he faces in the role and whether his advice is truly independent. . The former Dairy NZ principal scientist also speaks to Q+A about the lessons New Zealand learnt from its M. Bovis eradication programme, broader science sector reforms, and what changes to the school curriculum could mean for the future of STEM.

Pare tudo!Sem falsa modéstia, a barra continua alta aqui na Gregario.Agora é a vez de Fernando Blanco. Um apaixonado torcedor e pesquisador da história do ciclismo de estrada. Por um bom tempo, nos brindou com seus textos sob o título de CICLISMO PRO, no Facebook. Ele retorna ao GREGARIO para nos dar uma aula de história sobre essa figura única do ciclismo de estrada.Um bônus: ele fez uma lista que guiou a conversa com Alvaro Pacheco. Leia e comente!I. Grandes campeões que nunca gregariaram1. Eddy Merckx2. Lucien van Impe3. Bernard Thévenet4. Bernard Hinault5. Lance Armstrong6. Alberto Contador7. Primoz Roglic8. Tadej Pogacar II. Gregário que evoluiu para líder1. Fausto Coppi (ex-de Gino Bartali)2. Lauren Fignon (ex-de Bernard Hinault)3. Greg LeMond (ex-de Hinault e de Fignon)4. Miguel Indurain (ex-de Pedro Delgado) *5. Marco Pantani (ex-de Claudio Chiapucci)6. Chris Froome (ex-de Bradley Wiggins) *7. Vincenzo Nibali (ex-de Ivan Basso)8. Egan Bernal (ex-de Froome e Thomas)9. Jonas Vingegaard (ex-de Primoz Rogic) **Não confundir com co-liderançaIII. Grandes Rivalidades entre Líder e Gregário 1. Coppi x Bartali (Legnano, Giro 1940)2. Hinault x LeMond (La Vie Claire, Tour 1985)3. Roche x Vinsentini (Carrera, Giro 1987)4. Ullrich x Riis (Telekom, Tour 1987)5. Contador x Armstrong (Astana, Tour 2009)6. Froome x Wiggins (Not in race, 2012-13)IV. Campeões contratando gregários campeões1. Merckx – Van Springel (Molteni)2. Hinault – LeMond (Renault)3. Indurain – Jeff Bernard (Banesto)4. Armstrong – Roberto Heras (USPS)5. Petacchi – Zabel (Milram)6. Vingegaard – S.Yates (Visma)

What if the spaces we live, learn, and heal in could actually heal us back?In this powerful podcast interview, we sit down with Janet Roche, MDS, CAPS—nationally recognized design practitioner, educator, and founder of the Trauma-Informed Design Society. Janet is a pioneer in Trauma-Informed Design, helping reshape architecture and interior design to be inclusive, empathetic, and deeply human.We dive into:Her personal journey and the experiences that shaped her visionHow design can either harm or healThe myths around “good” design and disabilityCreating safe spaces for unseen traumaWhat it really costs to center inclusionThe tension between beauty and healingWhether you're a designer, educator, social worker, architect—or simply someone who believes in a more just and humane world—this episode will change how you see the spaces around you.

Tom Preston, co-author of COACHING POWER, is the founder of The Preston Associates, one of the world's premier executive coaching firms. With decades of experience coaching leaders across industries and geographies, he has helped organizations achieve extraordinary outcomes. A former private equity executive and bestselling author of Coach Yourself to Success, he brings deep insights and practical wisdom to his work.Luciana Nuñez, co-author of COACHING POWER, is an accomplished executive coach and former CEO with more than 20 years of leadership experience at Fortune 500 companies, including Bayer, Danone, and Roche. She blends her strategic expertise with a passion for mentoring, serving as a board member, investor, and advisor to entrepreneurs and executives worldwide.

How can biotech companies stay resilient and competitive when public sector funding becomes unpredictable? In this episode, host James Zanewicz, JD, LLM, RTTP, sits down with Adeyinka “Adey” Pierce-Watkins, MS, PMP—Director of Biodefense and Government Contracting at BDO USA—for a timely conversation on surviving and thriving in today's evolving federal funding landscape. From defense contracts to international partnerships, Adey shares practical guidance for life science leaders aiming to tap into strategic public funding opportunities. In this episode, you'll learn: How to identify and access alternative funding sources—including state, federal, and international opportunities. What biotech organizations need in place to be “government-ready” for grants, contracts, and urgent response funding. Why strategic planning, partnerships, and compliance infrastructure are essential to winning and executing federal awards. Whether you're pursuing BARDA grants, entering international consortia, or rethinking your risk exposure, this episode offers actionable insights to help biotech innovators chart a smarter path forward. Links: Connect with Adey Pierce, MS, PMP, and check out BDO USA. Connect with James Zanewicz, JD, LLM, RTTP and learn about Tulane Medicine Business Development and the School of Medicine. Learn more about the Cancer Prevention & Research Institute of Texas, TEDCO, and the California Institute for Regenerative Medicine. Learn more about Flagship Pioneering, Andreessen Horowitz, Novartis, Johnson & Johnson, and Roche. Learn more about HERA, Horizon Europe, AMED, and A*STAR. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU and make plans to attend October 28 & 29, 2025. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##Breaking News: Pfizer announces successful COVID-19 vaccine trialsIn a groundbreaking announcement, Pfizer revealed that their COVID-19 vaccine candidate has shown to be over 90% effective in preventing the virus. This news brings hope to the world as we continue to battle the global pandemic.##FDA approves new treatment for Alzheimer's diseaseThe FDA has approved a new treatment for Alzheimer's disease, marking a significant advancement in the fight against this debilitating condition. This approval could potentially change the lives of millions of patients and their families.##Johnson & Johnson recalls baby powder due to asbestos contaminationJohnson & Johnson has issued a voluntary recall of its baby powder products after trace amounts of asbestos were found in samples. This news has raised concerns about the safety of talc-based products and the potential risks they pose to consumers.##Novartis announces major breakthrough in cancer researchNovartis has made a significant breakthrough in cancer research with the development of a new targeted therapy that has shown promising results in clinical trials. This innovation has the potential to revolutionize cancer treatment and improve outcomes for patients.##Merck receives FDA approval for new diabetes drugMerck has received FDA approval for a new diabetes drug that offers another option for patients struggling to manage their condition. This approval expands treatment options and provides hope for those living with diabetes.##Roche acquires biotech company in multi-billion dollar dealRoche has announced the acquisition of a biotech company in a multi-billion dollar deal that will expand its portfolio and strengthen its position in the market. This strategic move demonstrates Roche's commitment to innovation and growth in the biotech sector.##Incyte collaborates with academic research center to develop new therapiesIncyte has formed a collaboration with an academic research center to develop new therapies for a range of diseases, including cancer and inflammatory conditions. This partnership brings together expertise from both sectors to accelerate the discovery and development of innovative treatments.##Overall, these recent developments in the pharmaceutical and biotech industry highlight the ongoing efforts to advance healthcare and improve patient outcomes. From groundbreaking vaccines to innovative therapies, these advancements are shaping the future of medicine and providing hope for patients worldwide.

The average workplace catering order size is up 12% to about $420. That's good news for restaurants, said Cindy Klein Roche, chief growth officer for ezCater, a platform that connects workplaces with dining concepts. But restaurants must optimize their online presence and present an appealing menu to get a piece of that growing pie. About 59% of those who place workplace orders are swayed by the menu, with budget-friendliness following close behind at 37%.While companies have been using catering as a return-to-office incentive, food has now evolved into a vehicle to drive productivity and collaboration, Roche explains. And employees who first try a restaurant at work will then return to that restaurant on their own or with a group for lunch or dinner. With B2B catering on the rise, she offers valuable insights as to how restaurants can boost that revenue stream, why breakfast and afternoon treats are growing as catering opportunities and where workplace catering is heading next. 

Der Basler Pharmakonzern Roche reagiert gelassen auf den US-Zollhammer. Der Branchenverband ist hingegen verunsichert.

In review: Lucas Wars by Laurent Hopman and Renaud Roche, published by Macmillan Publishing. In this episode, your hosts discuss the book, which explores George Lucas's journey from an aimless dreamer to a groundbreaking filmmaker and a key figure in the New Hollywood movement. But first, Mark and Becca go over the latest in Star Wars news.  Help us spread the word about the show Click here to subscribe via iTunes Click here to subscribe via RSS Click here to subscribe via Stitcher Click here to subscribe via Google Play Music Feedback and Promotion Follow us on Twitter @TarkinsTopShelf Like us on Facebook: Tarkin's Top Shelf Follow us on Instagram @TarkinsTopShelf Follow us on Threads  Follow us on Bluesky  

A four-decade long veteran of the professional salon industry, @RuthRoche is 8-time winner of the prestigious North American Hairstyling Awards, Redken Global Hair Educator, and renowned Coach. She is passionate about "empowering beauty professionals to create what they see" - and supporting the dreams and aspirations of more pros than we can count. Listen in for Ruths's take on creating a long, sustainable, and satisfying career.*Note: this episode was published originally as #6

On this episode of The Sideline Live podcast, I sit down with Eileen Roche, Director of Basketball Operations at Stanford. We dive into her incredible journey as a multi-sport athlete, coach, and long-time leader behind one of college basketball's most successful programs.Eileen and I met in September 2022 while I visited Stanford and clicked straight away. Growing up in Brooklyn she was an accomplished athlete in 3 sports; basketball, field hockey and softball. She decided to continue playing all three and attend Wesleyan University in Ohio, where she would excel was voted team captain in each sport. She would later be inducted into their hall of fame and pursued a career in coaching.During the episode shares insights on leadership, building a high-performance culture, and what it takes to support elite athletes both on and off the court. We explore her experience working alongside coaching legend Tara VanDerveer, how the role of basketball operations has evolved, and the behind-the-scenes details and culture that help make Stanford a powerhouse.From balancing academics and athletics to the challenges and opportunities women face in sport, Eileen offers practical advice for the next generation of leaders—whether coaches, players, or sport professionals. A serious operator on and off the court we discussed managing a busy programme as they move to the ACC schedule for the upcoming season. And yet she never fails to bring her infectious energy and enthusiasm to the programme every day. This episode is packed with stories, lessons, and reflections on what success really means in sport and life. So tune in to hear from one of my favourite people in sport. Follow The Sideline Live Social Media channels: ⁠⁠⁠⁠⁠https://twitter.com/thesidelinelive⁠⁠⁠ ⁠⁠⁠https://www.instagram.com/thesidelinelive/⁠⁠⁠ Recorded using Samson Q2 microphone, Edited using GarageBandIntro music, Watered Eyes by a talented Irish artist, Dillon Ward check him out ⁠⁠here⁠⁠ . If you are looking to set up your own podcast get in touch with the Prymal Productions team ⁠⁠⁠www.prymal.ie⁠⁠⁠

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: FDA approves the first fast-acting biosimilar insulin in the US, Tandem issues warning, DOJ stands up for remote monitoring in schools, GLP1 use protects against dementia, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX We've got the first and only biosimilar FDA approved and moving to market. Kirsty – insulin aspart, which is a biosimilar to Novolog will be available as a single-patient-use prefilled pen for subcutaneous use and a multiple-dose vial for subcutaneous and intravenous use. KIRSTY has been available in Europe and Canada since 2022. This same company makes Semglee, the first biosimilar for long acting? Sales of Insulin Aspart in the United States were approximately $1.9 billion in 2024, according to IQVIA. https://www.globenewswire.com/news-release/2025/07/15/3115973/0/en/Biocon-Biologics-Expands-Diabetes-Portfolio-with-FDA-Approval-of-Kirsty-the-First-and-Only-Interchangeable-Rapid-Acting-Insulin-Aspart-in-the-United-States.html XX Tandem Diabetes Care (Nasdaq:TNDM) has issued an urgent medical device correction for some t:slim X2 automated insulin pumps. In a July 22 notice, the San Diego-based company warned of pumps that may exhibit a higher rate of speaker failure. During normal use, the insulin pump software monitors current flowing through the speaker during use. Measurements that fall within a pre-determined range indicate a functioning speaker. Meanwhile, measurements falling outside the range indicate a speaker failure.   When the measurements land outside the expected range, the system declares a malfunction, referred to as “Malfunction 16.” If the pump declares this malfunction, insulin delivery will stop and the pump will no longer be operational. Malfunction 16 terminates communication between the pump and continuous glucose monitor (CGM), as well as the t:slim mobile app.   If not addressed, the issue can lead to hyperglycemia, which can result in hospitalization or medical intervention. The company reports 700 adverse events and 59 reported injuries to date, with no reports of death.   Tandem identified that certain speaker versions have a higher rate of Malfunction 16 events due to a wiring issue within the speaker. Users can continue using their pump but with added precautions because Malfunction 16 can occur at any time. They should use the t:slim mobile app with push notifications turned on so the app alerts them if the malfunction occurs, the company said.   Additionally, Tandem intends to release a software update aimed at enhancing the early detection of speaker failure. The update also introduces persistent vibration alarms to help reduce potential safety risk. Tandem plans to notify affected pump users when it makes the update available. https://www.drugdeliverybusiness.com/tandem-warns-insulin-pump-speaker-malfunction/ XX BIG WIN! The DOJ protects T1D rights again! The US Attorney's office for the Western District of Washington State reached a settlement with a public school district that once again confirms remotely monitoring students' CGMs is a reasonable accommodation that schools must provide to comply with the Americans with Disabilities Act. If its true for one state its true for all states under federal law! If your local schools still refuse to remotely monitor CGMs of their students, provide them with this letter to compel them to FOLLOWT1Ds and FOLLOW Federal Laws. If they still refuse contact us! https://followt1ds.org/ XX new study finds people taking GLP-1 agonists had a significantly lower cumulative risk of developing dementia, when compared to metformin users. Past studies show that people who have type 2 diabetes — a chronic condition where the body does not use its insulin properly — are at a higher risk of developing dementia. The study found that when comparing the neuroprotective abilities of two diabetes medications — metformin and glucagon-like peptide-1 receptor agonists (GLP-1 agonists) — participants taking GLP-1 agonists had a significantly lower cumulative risk of developing dementia, when compared to metformin.   https://www.medicalnewstoday.com/articles/glp-1s-may-offer-better-dementia-protection-than-metformin XX Front office changes coming to Dexcom.  CEO Kevin Sayer will step down  & give the reins to current Chief Operating Officer Jake Leach. Scheduled for January 1, 2026, Leach will also join Dexcom's board of directors where Sayer will remain  executive chairman. One of our frequent guests here.. Leach has worked at Dexcom for 21 years. He served as chief technology officer from 2018 to 2022 before he was named COO in late 2022. He was given the title of president in May. https://www.medtechdive.com/news/dexcom-ceo-change-kevin-sayer-jake-leach/756382/ XX A major international study has revealed that many children and young adults in Sub-Saharan Africa who are diagnosed with type 1 diabetes (T1D) may actually have a different, non-immune-based form of the condition. Unlike the traditional autoimmune version of T1D, this form appears to develop without the immune system attacking the insulin-producing cells. This finding could significantly reshape how diabetes is diagnosed and treated across the region, potentially leading to more precise care and better health outcomes. The researchers found that many young people in Sub-Saharan Africa diagnosed with T1D often don't have the usual markers in their blood (called islet autoantibodies) typically seen in people with T1D in other parts of the world. Specifically, 65% of participants with T1D in this region did not have islet autoantibodies. When the researchers compared this data to studies in the U.S., they found a smaller but significant proportion (15%) of Black participants diagnosed with T1D had a similar form of diabetes found in Sub-Saharan Africa – characterized by negative autoantibodies and a low T1D genetic risk score.   However, white Americans with T1D showed the typical autoimmune pattern, even if they didn't have detectable autoantibodies, their genetics still pointed to autoimmune diabetes.   “The identification of this T1D diabetes subtype in Sub-Saharan African populations and among individuals of African ancestry in the U.S. suggests a potential ancestral or genetic link,” Dabelea notes. “These findings highlight the need to consider alternative etiologies in this group and a deeper understanding of the underlying mechanisms may provide important insights for future prevention and treatment strategies.”     https://scitechdaily.com/new-diabetes-subtype-discovered-in-africa-challenges-global-assumptions/   XX Formal recognition for the specialty of Diabetology.   Diabetology is the specialty focused on the full continuum of diabetes care — encompassing diagnosis, treatment, prevention, technology integration, education, and cardiometabolic management. While it intersects with endocrinology, primary care, and public health, diabetology is uniquely defined by its depth and focus on diabetes alone.       The American College of Diabetology (ACD) is the national professional organization representing clinicians who specialize in diabetes care. ACD advances clinical excellence and education to improve the lives of those affected by diabetes. https://www.businesswire.com/news/home/20250725766248/en/American-College-of-Diabetology-Announces-Formal-Taxonomy-Classification-for-Diabetology   XX Tidepool announces cloud-to-cloud integration with Abbott's FreeStyle Libre portfolio. From the release: This integration allows people living with diabetes using the FreeStyle Libre portfolio to connect their data to their Tidepool account seamlessly. For healthcare providers, this means more comprehensive insights and streamlined workflows, with FreeStyle Libre systems data flowing continuously into the Tidepool Data Platform. https://www.tidepool.org/blog/abbott-freestyle-libre-integration-launched XX Stelo dexom ai food XX With high drug prices remaining an ongoing concern for U.S. politicians, Roche is considering following in the footsteps of some of its peers with a direct-to-consumer (DTC) model to cut out the middlemen.     About 50% of the money spent on drugs in the U.S. healthcare system goes straight to PBMs instead of the companies that create the medicines, Roche CEO Thomas Schinecker called out in a press conference on Thursday.   Bringing the drugs directly to the consumer could be a solution to positively impact pricing for patients “without destroying innovation,” Schinecker added on a separate Thursday call with investors, noting that the company has discussed the matter with the U.S. government and its Department of Health and Human Services. The pricing talks come after President Donald Trump inked a “Most Favored Nation” executive order in May, aiming to tie U.S. drug prices to lower prices in other developed nations. The plan was quickly called out by industry voices such as the PhRMA trade group, which labeled it a “bad deal” for U.S. patients. https://www.fiercepharma.com/pharma/roche-weighing-direct-consumer-drug-sales-ease-us-drug-pricing-woes-cut-out-pbms-ceo-says XX SAB BIO secures substantial $175M financing to advance T1D therapy with impressive investor lineup and extended cash runway until 2028. Most critically, this financing fully funds the pivotal Phase 2b SAFEGUARD study evaluating SAB-142 for delaying progression of autoimmune Type 1 diabetes in newly diagnosed patients. By extending the cash runway into mid-2028, SAB has effectively eliminated near-term financing risk and provided clear visibility through this crucial clinical trial and potential commercialization preparation. Participation from strategic investor Sanofi, along with new investors RA Capital Management, Commodore Capital, Vivo Capital, Blackstone Multi-Asset Investing, Spruce Street Capital, Forge Life Science Partners and Woodline Partners LP, and existing investors Sessa Capital, the T1D Fund, and ATW Partners         https://www.stocktitan.net/news/SABS/sab-bio-announces-oversubscribed-175-million-private-fwsf2t91ek4z.html   XX In a landmark 14-year study, researchers have found that artificially sweetened drinks raise the risk of developing type 2 diabetes by more than a third, significantly higher than those loaded with sugar. It challenges the long-standing perception of diet drinks being a healthier alternative and suggests they may carry metabolic risks of their own. In the first longitudinal study of its kind, led by Monash University, researchers tracked 36,608 participants over an average period of 13.9 years to assess how both sugar-sweetened beverages (SSBs) and artificially sweetened beverages (ASBs) impacted health outcomes. The self-reported health data, from the Melbourne Collaborative Cohort Study, was drawn from participants aged 40 to 69 years at the time of recruitment.   What they found was that drinking just one can of artificially sweetened soda increased the risk of developing type 2 diabetes by 38%, compared to people who didn't consume these drinks at all. For those consuming the same amount of sugary drinks, the risk was 23% higher. This suggests there's more than obesity at play. The researchers believe this result is due to an independent metabolic effect, possibly gut microbiome disruption or a change in glucose metabolism.   While the study didn't identify which artificial sweeteners were at play,   Evidence suggests that artificial sweeteners can alter the composition and function of gut bacteria, leading to glucose intolerance – a precursor to type 2 diabetes. And that some sweeteners may trigger insulin release, desensitize metabolic responses over time, or confuse the body's glucose regulation system – even without actual sugar in the picture.   Another hypothesis is that regular exposure to the kind of intense sweetness that artificial products deliver may condition the body to anticipate sugar calories that never come, affecting appetite regulation, insulin sensitivity and broader metabolic pathways. However, the authors suggest that how sweeteners affect the gut microbiota and glucose regulation are the most likely drivers of increased diabetes risk.   https://newatlas.com/diet-nutrition/one-drink-diabetes-risk/ XX After months of deliberation, information gathering and public testimony, a state board unanimously agreed Monday that two common medications for type-2 diabetes and other conditions appear to pose an affordability challenge to the state and Marylanders.   The state Prescription Drug Affordability Board approved two resolutions saying that prescription drugs Jardiance and Farxiga likely pose an “an affordability challenge for the state health care system” and the state should look for ways to bring down those costs.   Health care advocates call the long-awaited resolution an “important first step” in the process in bringing down prescription costs for those on the state's health plan.       That milestone has been years in the making. Created in 2019 by the General Assembly, the Prescription Drug Affordability Board was slow to launch due in part to a veto from former Gov. Larry Hogan (R) amid pandemic-induced economic uncertainty in 2020 that delayed the board's formation. The board also cited out-of-pocket costs for consumers and state and local spending on those drugs as indicators that there may be an affordability challenge.   The board will now look at options to address the potential affordability challenge, which could include setting an upper payment limit on those drugs. But it's not clear when the state will see cost savings.   That said, some members of the health care system and the pharmaceutical industry say that policies such as upper payment limits could weaken access to life-saving drugs. Others say that the board has not engaged enough viewpoints from the health care industry. https://marylandmatters.org/2025/07/29/state-board-determines-two-type-2-diabetes-drugs-may-be-unaffordable/   XX One year after it was revealed that Chrissy Teigen and John Legend's son, Miles, was diagnosed with type 1 diabetes, Teigen is revealing how she's making her son feel more included. Teigen first opened up about her 7-year-old son's diagnosis after she and her two oldest kids, Miles and 9-year-old daughter Luna were at the 2024 summer Olympics cheering on Simone Biles. Teigen posted a photo of Miles and Luna holding up a sign. Also visible in the picture was the insulin pump on Miles' arm. Now, Teigen is sharing some insight into how she's making Miles more comfortable with having type 1 diabetes, including giving LeBron James' Barbie doll type 1 diabetes as well. In a video shared on Instagram, Teigen is seen taking the T1D Barbie, removing her insulin pump and gluing the pump onto LeBron James' Barbie. “Turning T1D Barbie into T1D Lebron James for my son,” Teigen captioned the video, revealing James is Miles' hero. 41 million followers https://www.yahoo.com/lifestyle/articles/chrissy-teigen-gives-lebron-james-154608782.html  

Healthcare and technology stakeholders pledge to make healthcare data sharing easier following a meeting at the White House. A federal judge blocks Arkansas's strict pharmacy benefit manager law. And, Swiss drugmaker Roche weighs direct-to-consumer drug sales. Those stories on today's episode of the Gist Healthcare podcast. Hosted on Acast. See acast.com/privacy for more information.

Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy Elevidys and growing scrutiny over the company’s transparency following multiple patient deaths. In this week’s episode of "The Top Line," we explore Sarepta’s brief standoff with the FDA over Elevidys, a short-lived marketing pause, and the regulator’s surprise reversal on the treatment. Fierce Pharma’s Fraiser Kansteiner and Angus Liu sit down with Fierce Biotech’s Gabrielle Masson to recap the story and discuss the broader implications the Elevidys saga may have for gene therapy, the FDA and the pharmaceutical industry. To learn more about the topics in this episode: Sarepta pivots to siRNA and lays off 500 staffers as Elevidys gets box warning Sarepta LGMD trials all hit by FDA hold amid newly surfaced safety concerns over gene therapy Sarepta, bowing to FDA pressure, pauses shipments of Duchenne gene therapy Elevidys FDA takes U-turn on Sarepta's Elevidys, backing Duchenne gene therapy again in ambulatory patients Analysts demand transparency after Sarepta's roundabout disclosure of 3rd patient death Roche won't throw in the towel after DMD gene therapy Elevidys' rebuff in Europe See omnystudio.com/listener for privacy information.

Howie and Harlan discuss Dr. Vinay Prasad's departure from the FDA after a backlash against his decisions on Sarepta's Duchenne muscular dystrophy gene therapy. Also examined: AI in clinical settings, changes in NIH grantmaking, and the 60th anniversary of Medicare and Medicaid. Links: Sarepta and the FDA “STAT breaks down the confusing, heartbreaking Sarepta saga” “Sarepta Therapeutics' Duchenne therapy faces ‘arduous' path back to market, senior FDA official says” “For many Duchenne families, halt to gene therapy is heartbreak upon heartbreak” “FDA launches probe into new Elevidys death as Sarepta, Roche stress gene therapy not at fault” “FDA Recommends Removal of Voluntary Hold for Elevidys for Ambulatory Patients” “FDA takes U-turn on Sarepta's Elevidys, backing Duchenne gene therapy again in ambulatory patients” “Controversial FDA official Dr. Vinay Prasad departs agency” “Top F.D.A. Vaccine Official Resigns, Citing Kennedy's ‘Misinformation and Lies'” “Vinay Prasad Is a Bernie Sanders Acolyte in MAHA Drag” “Timeline: The Rise and Fall of Vioxx” “What have we learnt from Vioxx?” THC in pizza dough “C.D.C. Ties 85 Cases of THC-Related Symptoms to Wisconsin Restaurant” “Tetrahydrocannabinol Intoxication from Food at a Restaurant — Wisconsin, October 2024” NIH funding “NIH is shrinking the number of research projects it funds due to a new Trump policy” NIH: Supporting Fairness and Originality in NIH Research Applications “Fearful of AI-generated grant proposals, NIH limits scientists to six applications per year” “Trump budget draft proposes NIH consolidation and 40% spending cut” Raw milk “Outbreak of Salmonella Typhimurium Infections Linked to Commercially Distributed Raw Milk — California and Four Other States, September 2023–March 2024” “The Dangers of Raw Milk: Unpasteurized Milk Can Pose a Serious Health Risk” AI in healthcare update “Ambience Healthcare Announces $243 Million Series C to Scale its AI Platform for Health Systems” “As ambient scribes face off, Doximity lures doctors with a free option” Aidoc: “AI Empowering Radiologists” “Clinical Implementation of a Combined Artificial Intelligence and Natural Language Processing Quality Assurance Program for Pulmonary Nodule Detection in the Emergency Department Setting” “Large Language Models as an Inexpensive and Effective Extra Set of Eyes in Radiology Reporting” “Current Trends in Remote and Flexible Work Options in Radiology and Perception of Impact on Radiologist Well-being” Medicare and Medicaid 60th anniversary CMS' program history “Medicare and Medicaid turn 60 – and face historic cuts decades in the making” UnitedHealth and Medicare Advantage “UnitedHealth says 2025 earnings will be worse than expected as high medical costs dog insurers” “UnitedHealthcare to exit certain Medicare Advantage markets as costs balloon, impacting 600K enrollees” “Novo Nordisk slides further on US competition, new CEO concerns” “Dems Must Really Fix Medicaid, Not Just Undo Trump's Damage to It”   Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.

In this heart-opening episode of the Spiritual Journey Podcast, host Nimesh Radia is joined by the radiant Lisa Roche—founder of Nagare Life and host of the Find Your Flow podcast—for a profound conversation about navigating the spiritual shift, healing through courage, and embracing the divine human experience.Lisa opens up about her deeply personal awakening journey, from facing debilitating physical challenges to receiving divine guidance that changed her life forever. Together, Nimesh and Lisa explore what it means to live in alignment during times of fear, the importance of sacred containers for healing, and how we can all begin to trust the quiet voice within. This episode is a soul-to-soul reminder that we are never alone, and the healing path often starts with one small act of courage.Together, Nimesh and Lisa explore:

The Sarepta saga continued into another week as the FDA recommended that the voluntary hold on the company's Duchenne muscular dystrophy gene therapy be lifted for ambulatory patients, after determining that the death of an 8-year-old Brazilian Duchenne patient who had received Elevidys' was not caused by the drug.  Sarepta's stock has swung wildly and its transparency questioned after it elected not to reveal the death of a third patient—a participant in a trial of a gene therapy for limb girdle muscular dystrophy—during a business update last week.    Speaking of entities—or individuals—who have trouble staying out of the news, Health Secretary Robert F. Kennedy Jr. plans to dissolve the U.S. Preventive Services Task Force because it is “too woke.” Also on Monday, Kennedy addressed what he called the “broken” vaccine injury compensation program. Without offering details, he vowed to “fix” the U.S.'s VICP and return it to its “original Congressional intent.”   On the business side of the biopharma house, Q2 earnings are in full swing, with AstraZeneca announcing estimate-beating numbers and CEO Pascal Soriot saying the world “needs to share” in global pharma R&D, while Merck cut $3 billion to support an aggressive launch schedule. Meanwhile, a week ahead of its own earnings report, Novo Nordisk named a new CEO and lowered its 2025 sales guidance for the second time this year.   In clinical development, the Alzheimer's Association Annual Conference is underway in Toronto, with Roche's trontinemab the standout so far. In a Phase Ib/IIa trial, the next-gen anti-amyloid antibody rapidly cleared amyloid from the brains of patients with Alzheimer's disease after just seven months—besting the 18-month timeframe for Biogen and Eisai's Leqembi and Eli Lilly's Kisunla. While Leqembi and Kisunla have shown some progress is slowing down the progression of Alzheimer's, their effect size is modest and they don't work for all patients—leaving plenty of room for symptomatic treatments, such as those being developed by Bristol Myers Squibb and Acadia Pharmaceuticals. The space is gearing up for several readouts, for both symptomatic and disease-modifying therapies alike.   And in BioPharm Executive this week, we dig into the top VC rounds so far this year and highlight a few scrappy biotechs walking the solo road.  

Can healing yourself really help heal the world?This week, Thomas sits down with Amandine Roche, a human rights and women's empowerment expert with more than 20 years of experience with the United Nations and European Union. Amandine's extensive work in conflict zones worldwide was driven by a deep, personal quest for healing from childhood trauma. But the work itself took a toll on her mental and physical health, leading her on a journey of healing that uncovered an essential core truth that she now works to spread: we must have inner peace if we want to work for outer peace.Amandine shares beautifully honest details from her own personal struggles and offers a unique perspective on embracing femininity in human rights work and all forms of leadership. She and Thomas explore the need for collective spaces and new skills to digest world events and prevent the repetition of painful social and political patterns.It's an empowering conversation that highlights the absolute necessity of self-alignment and inner healing in humanitarian work and any type of effort toward peace and harmony in a world in crisis.✨ Click here to watch the video version of this episode on YouTube:

In this thought-provoking episode of Truth Works, organizational visionary Michele Zanini joins Jessica Neal and Bob Sutton to unpack the tyranny of bureaucracy and the bold promise of humanocracy. Co-author of the updated book Humanocracy, Michele explains why traditional management systems fail to inspire innovation, agility, or meaning—and how companies like Netflix, Roche, and even the U.S. Army are rewriting the rules.Together, they explore:Why companies become bureaucratic over timeThe flipside: unleashing resourceful people instead of controlling themRadical models of leadership, autonomy, and peer accountabilityHow culture is built through operating systems—not slogansIf you're a founder, HR leader, or executive trying to unshackle your team from inertia and unleash real human potential, this one is for you.

Today we'll focus on a major shift in the treatment of myasthenia gravis -- as a wave of new therapies is changing how we treat this disease. Who should be considered for these new treatments? And what else is in the pipeline?   Our guest today is Dr.  Gil Wolfe, a neuromuscular neurologist at the University of Buffalo State University of New York, Jacob School of Medicine and Biomedical Sciences. Dr. Wolfe was interviewed by Dr. Ioannis Karakis, adjunct professor of neurology at Emory University School of Medicine.   References: https://www.nature.com/articles/s41598-024-79918-7   Disclosures: Dr. Wolfe discloses: Consultant for: Alexion, Argenx, BPL, Cartesian, Canopy, Grifols, Johnson & Johnson, Takeda, UCB; Speaker Bureau for: Grifols, Alexion, UCB; Grant/Research support from: ArgenX, Ra/UCB, Immunovant, Roche, Alexion, Sanofi

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. The European Medicines Agency's CHMP did not recommend approving Elevidys for ambulatory patients with Duchenne muscular dystrophy, dealing a blow to Sarepta. FDA is rumored to request new data for Elevidys, leading to uncertainty as FDA considers a new study for the drug. In other news, Eli Lilly commits $856 million to Gate Bioscience for a new class of medicines, while Rocket trims headcount and pipeline focus. Roche also drops an early obesity asset as layoffs continue in the biopharma industry, with companies like Adicet optimizing their pipelines. Novartis makes a billion-dollar drug discovery deal with Matchpoint, and the FDA opens a pilot run of the commissioner voucher program.Stay tuned for more updates on the latest developments in the pharmaceutical and biotech world.

Analizamos los valores clave en el Viejo Continente de la mano de Pablo García, director general de Diovacons-Alphavalue. Miramos al pacto comercial entre la UE y EE.UU, el sector automovilístico, ST Micro, ASML, Infineon, Roche, Sanofi, Novartis, Heineken, Prosibiensat y Media for Europe.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Roche has dropped an early-stage obesity asset, CT-173, citing lack of competitiveness. Novartis has entered into a drug discovery deal with Matchpoint Therapeutics, acquiring global rights on all molecules for several inflammatory diseases. AstraZeneca claims a Phase III win with its nanobody treatment for myasthenia gravis. Second-quarter earnings season is approaching, and biotechs to watch include Sarepta and others facing challenges in the biopharma industry. Genentech downsizes as priorities shift, and GSK's comeback for Blenrep is on pause as the FDA delays its decision. The FDA's lack of transparency has tarnished Sarepta's reputation after patient deaths triggered an FDA battle. Opportunities in the industry include roles like Quality Specialist at CSL and Clinical Research Physician at Eli Lilly and Company.

Roche nimmt Krebsmedikament Lunsumio vom Schweizer Markt, Schüsse auf Hilfskorridore in Gaza, «Earth Overshoot Day»: Wie nachhaltigeres Leben aussehen könnte, Neuverfilmung Superhelden-Saga «The Fantastic Four: First Steps»

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. The FDA has initiated a voucher program to address lower drug prices and boost domestic investment, with up to five companies being selected based on national priorities. Roche has halted shipments of Sarepta's Elevidys gene therapy after reports of patient deaths. Sarepta is under FDA scrutiny following a third patient death, while the agency welcomes a new top drug regulator and rejects multiple new drugs from entering the market. Insights from women in biopharma highlight the importance of resilience. Zhen Li, an engineer, is playing a crucial role in shaping the field of siRNA. Research suggests that GLP-1s may offer protection against neurodegenerative diseases. Dispatch Bio enters the scene with a substantial $216 million investment for universal CAR T therapy. Sarepta complies with an FDA request to suspend US shipments of Elevidys, raising concerns about transparency and impacting the company's reputation. Replimune experiences a significant drop in stock value following an FDA rejection, while AstraZeneca makes a bold $50 billion investment in US manufacturing to prepare for potential tariffs. Thank you for tuning in to Pharma and Biotech daily for the latest updates in the industry.

Global equity markets rally on US-Japan trade deal progress, sparking hopes for EU agreements, with equities surging and gold easing. Japan's Nikkei 225 reaches a new all-time high, as does the S&P 500. In earnings: Alphabet surprises positively, while Tesla disappoints. Companies reporting today include industry giants like Nestle, Roche, Deutsche Bank, and LVMH. The ECB is not expected to cut rates today, with the market's focus on its outlook. Carsten Menke, Head of Next Generation Research, discusses China's historic new hydropower project – which is six times bigger than the Three Gorges Dam – and explores its potential impact on iron ore and steel prices.(00:00) - Introduction: Helen Freer, Investment Writing (00:25) - Markets wrap-up: Mike Rauber, Investment Writing (05:58) - Iron ore and steel: Carsten Menke, Head of Next Generation Research (09:51) - Closing remarks: Helen Freer, Investment Writing Would you like to support this show? Please leave us a review and star rating on Apple Podcasts, Spotify or wherever you get your podcasts.

Just a few weeks ago, it seemed like Sarepta had weathered a spate of bad news, after two patients died from liver injuries from its Duchenne muscular dystrophy gene therapy Elevidys. Then came news of a third patient death. Last Wednesday, the company announced a major restructuring and 500-person layoff.  Then, in just a few days time, Sarepta Therapeutics went from enjoying a notable stock bump in response to that corporate update to its lowest price in nearly 10 years as it halts shipments of Elevidys. In addition to requesting the shipment hold, the FDA revoked the company's technology platform designation and paused all clinical trials for Sarepta's limb-girdle muscular dystrophy (LGMD) gene therapy. The turmoil was set in motion by media reports that a patient who received the LGMD treatment had died—a fact the company chose not to disclose during an investor call. In other news, the FDA's Center for Drug Evaluation and Research gets a new director in biotech veteran George Tidmarsh, also an adjunct professor of pediatrics and neonatology at Stanford University's School of Medicine. Tidmarsh enters the agency at a time of mass layoffs as well as voluntary departures. Meanwhile, Replimmune and Roche suffer FDA rejections as therapies from Otsuka/Lundbeck and GSK fail to earn adcomm support, as the bar for acceptable controls and demonstrations of efficacy continue to change under FDA commissioner Marty Makary and CBER director Vinay Prasad.  Finally, Big Pharmas continue to pump billions into U.S. manufacturing, with Biogen and AstraZeneca joining the list of companies to have made such pledges, pledging $2 billion and $50 billion, respectively. These latest announcements come as President Donald Trump reiterates that pharma-specific tariffs of up to 200% could come as soon as Aug. 1. 

In this episode, we conclude the comprehensive series on Gary Hamel and 'Humanocracy,' diving deep into the principles and practices that can transform entrenched bureaucracies into more dynamic and innovative organizations. Host Aidan interviews Gary Hamel to discuss the persistent issue of bureaucracy stifling economic growth and the groundbreaking transformation at Roche as a case study. The conversation covers the increasing bureaucracy in global companies, the decline in productivity, and innovative methods like outcome-based planning and cross-functional squads to elevate organizational efficiency. The episode also emphasizes personal accountability and offers actionable steps for leaders aiming to foster a more adaptive and resilient work environment. This informative discussion is a must-watch for CEOs and business leaders looking to revolutionize their companies.   00:00 Introduction and Giveaway Announcement 00:52 The Problem with Bureaucracy in Organizations 06:16 Case Study: Roche's Transformation 11:16 Leadership Reboot and Principles at Roche 20:31 Implementing Change: Design Teams and I Squads 26:34 Outcome-Based Planning and Resource Allocation 29:53 Resource Allocation and Organizational Ethos 31:16 Resilience in the Face of Challenges 32:59 Leadership and Change Management 37:47 Cross-Functional Squads and Collaboration 42:43 Patient-Centric Approach 46:31 Personal Accountability and Bureaucracy 50:30 Experimentation and Innovation 56:22 Conclusion and Final Thoughts   Find Gary 

Restaurant catering — and the tech that powers it — is hot, hot, hot. At nearly 20 years old, ezCater is poised to take advantage of the renewed interest from office workers and the restaurants that serve them. In this episode we talk about the evolution of catering, the tech that supports it, and why a little reassurance and hand-holding goes a long way with corporate clients. 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.George Tidmarsh, a biopharma veteran and adjunct professor at Stanford's medical school, has been appointed as the new head of the FDA's Center for Drug Evaluation and Research (CDER). His extensive industry experience will be valuable in his new government position. Data secrecy among cell and gene therapy developers is hindering progress in the field, causing fragmentation, stalling innovation, and delaying access to treatments. Meanwhile, Sarepta is facing challenges with its elevidys shipments and has lost platform designation for its technology. At the same time, Roche's phase III trial in COPD has failed, impacting the market path for astegolimab. Layoffs are happening at companies like GSK, Sail, and BioNTech. Experts are exploring new ways to overcome barriers in cell therapy production.Data secrecy among cell and gene therapy developers continues to hinder progress and access to treatments. Acadia has introduced a new team and pipeline with ambitious goals. Patients are fighting for access to Brainstorm's ALS drug after promising real-world data. Moderna's withdrawal of its flu vaccine has left combination flu/COVID-19 vaccines in limbo. In other news, Sarepta is facing challenges with its DMD gene therapy, Ultragenyx's gene therapy for Sanfilippo syndrome is rejected by the FDA, GSK's Blenrep loses an adcomm vote, and BMS' anemia drug Reblozyl fails a Phase III trial. The FDA is experiencing layoffs and employee turnover amid an overhaul. Vinay Prasad overruled reviewers on Moderna's COVID-19 shot for kids. Upcoming events include a webinar on AI for real-world research and job opportunities in the biopharma industry. Readers are encouraged to provide feedback and suggest topics for future coverage.

Les journalistes et experts de RFI répondent également à vos questions sur les investissements chinois en Afrique, le trafic illégal de bois russe en Europe et le remaniement gouvernemental en Ukraine. Niger : la plus grosse roche de Mars vendue aux enchères  Découverte en 2021 dans la région d'Agadez, au nord du Niger, une météorite d'origine martienne a été vendue ce 17 juillet aux enchères à New York pour 5,3 millions de dollars. Une transaction record pour un fragment extraterrestre. Comment cette roche de Mars a-t-elle été découverte ? Le Niger a-t-il tiré un bénéfice économique ou scientifique de cette découverte ? Avec Welly Diallo, journaliste au service Afrique de RFI. Investissements chinois : opportunité pour l'Afrique ou nouvelle tutelle étrangère ?   La Chine multiplie ses investissements sur le continent africain avec 39 milliards de dollars en 2025. Ces investissements représentent-ils une réelle opportunité pour le développement de l'Afrique ? Peut-on y voir une nouvelle forme de dépendance ? Avec Emmanuel Véron, enseignant-chercheur associé à l'Inalco, spécialiste de la Chine.  Union européenne : trafic illégal de bois russe malgré les sanctions  Malgré les sanctions imposées à la Russie, des millions d'euros de bois illégal continuent d'affluer vers l'Union européenne. Comment expliquer l'entrée de ce bois russe en Europe ? Pourquoi les pays comme la Turquie, la Géorgie ou la Chine sont-ils utilisés comme points de transit dans ce trafic de bois ? Avec Yang Mei, journaliste au service environnement-climat et au service en langue chinoise de RFI.  Ukraine : la nouvelle Première ministre sous le feu des critiques  Volodymyr Zelensky a opéré un remaniement gouvernemental en nommant Ioulia Svyrydenko au poste de Première ministre, pourtant très critiquée à cause de sa proximité avec le président. En quoi sa nomination pourrait-elle renforcer l'influence de Zelensky sur le gouvernement ? Avec Adrien Nonjon, chercheur spécialiste de l'Ukraine. 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Johnson & Johnson reported second-quarter earnings of $23.7 billion, driven by cancer and neuroscience drugs, exceeding analyst expectations. CEO Joaquin Duato set a target of $50 billion in oncology sales by 2030. Despite challenges in the industry, Johnson & Johnson remains optimistic about its oncology sales target as the biotech industry continues to navigate the evolving landscape of drug development and funding.In a difficult investing environment where IPOs are not guaranteed, AI-focused biotech unicorns are facing challenges in securing funding. GSK's Blenrep is facing setbacks as the FDA questions its efficacy in treating multiple myeloma, while AstraZeneca's amyloidosis asset failed to improve survival in a late-stage trial. The industry is also seeing the rise of women leaders like Audrey Greenberg and the team at Acadia, who are making significant contributions to the field.Biospace is launching a new weekly newsletter focused on critical manufacturing issues in the biopharma industry, covering developments and impacts on companies such as Roche, Sanofi, and Johnson & Johnson. The newsletter aims to provide deep dives, analysis, and roundups of the biggest manufacturing stories of the week every Tuesday. Stay informed with weekly analysis and updates on the changing landscape of manufacturing in the U.S.

What does it truly mean to lead when the world around you crumbles and rebuilds itself?This episode features host Denis Gianoutsos' most powerful conversations with two extraordinary leaders. Dr. Nadya Zhexembayeva, born to political dissidents in Soviet Kazakhstan, witnessed her world collapse overnight—yet discovered that leadership is a dynamic space we enter and exit, not a fixed title. Ken Miller, a healthcare executive with 32 years of global experience, reveals the athletic mindset required for modern leadership and why our most outstanding teachers are found in our closest relationships, not boardrooms.Join Denis Gianoutsos for this transformative mashup—your perspective on leadership may never be the same.EP 221 - Dr. Nadya Zhexembayeva: Leadership as a Dynamic Space: From Soviet Collapse to Revolutionary ThinkingBorn in Soviet Kazakhstan to political dissidents, witnessed sudden USSR collapse, creating a complete vacuumRedefines leadership as a space you enter and exit daily, not a fixed title or position.Draws from Kazakh nomadic culture,e viewing leadership as a dynamic circle larger than any individualIdentifies daughter and parents as most significant leadership influences, emphasizing self-love before leading othersEP 225 - Ken Miller: Healthcare Leadership and the Athletic Mindset: Building Legacy Through Purpose32 years in healthcare at companies like Sanofi, Pfizer, Roche, choosing impact over just profitDescribes leaders as athletes - highly competitive with a tireless appetite for success and sacrificeEmphasizes continuous learning and personal development rather than relying on organizationsCites Dr. Martin Luther King Jr. as a favorite leader for authenticity and fighting for something bigger than himselfKey Quotes:"Leadership for me is a space. You enter and exit many times a day." - Dr. Nadya Zhexembayeva"You've gotta have a work ethic, which is second to none, to really have an impact around the world." - Ken MillerThe 10 Proven Ways to Lead and Thrive in Today's World - FREE Executive Guide Download https://crm.leadingchangepartners.com/10-ways-to-lead Connect with Denis:Email: denis@leadingchangepartners.comWebsite: www.LeadingChangePartners.com Facebook: https://www.facebook.com/denisgianoutsos LinkedIn: https://www.linkedin.com/in/denisgianoutsos/ Instagram: https://www.instagram.com/leadershipischanging/ YouTube Channel: https://www.youtube.com/@DenisGianoutsos

Cet été, retrouvez le meilleur d'Au cœur de l'Histoire, avec Virginie Girod ! Le 11 novembre 1918, l'armistice est signé dans la clairière de Rethondes, à Compiègne, mettant fin à la première guerre totale de l'Histoire. Après la victoire, l'on rend hommage à ceux qui ont servi la patrie au péril de leur vie. Parmi eux, se trouve Albert Roche (1885-1939), jeune paysan originaire de la Drôme qui aurait capturé pas moins de 1180 soldats allemands à lui seul, bravant la peur et la mort dans l'enfer des tranchées. Le 27 novembre, à Strasbourg, il est décoré par le maréchal Foch qui le surnomme "le premier soldat de France". Mais quelle est la part du mythe dans l'incroyable histoire des exploits d'Albert Roche ?Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Cet été, retrouvez le meilleur d'Au cœur de l'Histoire, avec Virginie Girod ! À l'occasion de la fête national, découvrez ou redécouvrez l'histoire d'un héros français oublié. Le 28 juin 1914, l'assassinat de l'archiduc François-Ferdinand d'Autriche met le feu aux poudres et plonge l'Europe dans la Première Guerre mondiale. Alors qu'en France, la mobilisation est annoncée, un jeune paysan de la Drôme veut partir au front et servir sa patrie. Exempté de service militaire à cause d'un physique chétif, Albert Roche (1885-1939) force le destin et parvient à être envoyé en première ligne, au sein du 27e bataillon des chasseurs alpins. Agé de vingt ans, le jeune soldat se livre alors à de remarquables faits d'armes.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

A tome trial preview featuring most of the Roche dynasty.Sign up to BIKMO for the best bike insurance in the world!Sign up and show your support to NSF - Live in France! Hosted on Acast. See acast.com/privacy for more information.

Invertir en salud para crecer como sociedad.

Dans cet épisode, on parle d'une punition ratée, d'Hélène Rollès, et du talent caché de Vitaa, entre autres.SOURCEShttps://www.placegrenet.fr/2019/03/10/albert-roche-heros-oublie/530363https://www.facebook.com/watch/?v=1054611688304379https://www.penseemiliterre.fr/albert-roche-1895-1939-premier-soldat-de-france_114720_1013077.htmlhttps://www.instantculture.fr/2021/01/23/albert-severin-roche-le-premier-soldat-de-france/---Retrouvez Vulgaire sur Instagram : @vulgaire_lepodcast---Un podcast de Marine Baousson---Écrit et produit par Marine Baousson / Studio BruneRéalisé par Antoine OlierMusique de Guillaume Bérat du collectif BranksIllustré par Juliette PoneyLa transcription de cet épisode est dispo ici : https://drive.google.com/drive/folders/12IDU2ly4oBrzBHWMPcRd9HNZJe_d7NJF---VULGAIREUn podcast de Marine Baousson et Marie Missetproduit par Marine Baousson / Studio BruneRéalisé par Antoine OlierGénérique : Romain BaoussonGraphisme et illustrations : Juliette PoneyCapsules Vidéo : Emma Estevezprogrammation : Louise Tempéreau Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

We kick off this Spotlight at the Western States 100, where much of the buzz centered on David Roche's DNF. Roche, a polarizing figure who promised to “science the shit” out of the race, faced unfair criticism both before and after the race, and Ross reflects on how the scientific process often works best when the "hypothesis" fails, and why confronting failed hypotheses to explain under-performance is more beneficial than riding a wave of success .The "science the shit out of it" theme continues with Nike's hyped attempt to help Faith Kipyegon break the 4-minute mile. It didn't just fall short—it missed by a long shot, with Kipyegon never really giving the barrier a scare with a pacing strategy that reveals they all knew it was not truly feasible. Ross and Gareth unpack the science, pseudoscience and "hacks" behind the effort, with honorable mentions for the obviously flawed claims by scientists about drafting benefits, and criticism of many media who parroted hype points without critical thought. We wonder what the athlete who could break 4 looks like, and postulate that they probably don't exist. Yet. From ultra to ultra-short, we shift to the 100m, where Kishane Thompson clocked a blistering 9.75s—the fastest in a decade, leading Gareth to wonder why sprinting seems to have plateaued post-Bolt?In Center Stage (37:14), legal expert Matt Kemp joins us to dissect a recent rugby case where a player successfully sued an opponent for causing a spinal injury with a reckless off-the-ball collision. Could this open the door to more civil claims in contact sports? Matt explains the legal standards around recklessness and duty of care. Ross Replies (1:15:23) to Discourse member Paul on the purpose of sports science and what "truth" means when studies can't be replicated?And in Listener Lens (1:24:15), we explore ATP's role in exercise, wonder whether you can ever “run out” of it, and how the purpose of metabolism is to keep it in good supply. And Finally (1:31:17), we invite you all to join our Tour de France Fantasy League, and see if you can top Gareth and Ross' picks in our two leagues!Join DiscourseJoin the Discourse community, to hang out with the racers, analysts, legal experts, coaches and experts, by making a small monthly pledge at PatreonLinksAnalysis of the 100m event that inspired our 100m chatGymnastic medalists are getting olderReport on the decision ruling in favour of a player injured by opponentMatt, our new legal expert, is a partner at Becker Kemp Solicitors & AttorneysRoss' reply to Tony on the ATP depletion question - members onlyTDF FANTASY LEAGUE - play one of our two leagues Hosted on Acast. See acast.com/privacy for more information.

نوید ناظمیان یکی از شناخته‌شده‌ترین کوچ‌های اجرایی در جهان است که در هدایت رهبران ارشد برای ورود موفق به نقش‌های مدیریتی سطح C تخصص دارد. او بیش از ۲۶ سال تجربه بین‌المللی دارد و در شرکت‌های بزرگی مانند وودافون، آدیداس، جنرال الکتریک، BAT و رُوش (Roche) در جایگاه‌های ارشد منابع انسانی فعالیت کرده است. این تجربیات به او دیدگاه عمیقی نسبت به چالش‌های مدیران در بازارهای نوظهور و توسعه‌یافته داده است.00:00:00 پیشگفتار00:01:30 معرفی نوید از HR تا نویسندگی و کوچینگ00:02:56 شروع مسیر: چرا دانشگاه نرفتم؟ 00:07:12 انقلاب شغلی: ورود به دنیای منابع انسانی 00:13:23 تجربه ۲۰ ساله: چرا هرگز یک صنعت را تکرار نکردم؟00:19:22 لحظه سرنوشت‌ساز: داستان مدیری که نیاز به کوچ داشت 00:33:10 چگونه یک کوچ حرفه‌ای پیدا کنیم؟ ۱۰ معیار کلیدی 00:43:40 برنامه کوچینگ ۱۲ ماهه از ارزیابی تا تحول01:13:20 فراتر از سوال: کوچینگ، منتورینگ و ادوایزری01:40:56 کوچ انسانی یا هوش مصنوعی تفاوت‌ها کجاست؟ Navid Nazemian is a globally recognized executive coach, specializing in guiding senior leaders through successful transitions into C-suite roles. With over 26 years of international experience, he has held senior HR positions at leading companies such as Vodafone, Adidas, GE, BAT, and Roche, providing him with firsthand insight into the complexities faced by executives in both emerging and developed marketsNavid Nazemian | نوید ناظمیانhttps://www.linkedin.com/in/navidnazemian